Ugur Eskiocak
Chief Executive Officer & Co-Founder Voro Therapeutics
Ugur Eskiocak, PhD is the Co-Founder and CEO of Voro Therapeutics. Voro is developing oncology therapeutics through its category-defining, tumor-activated biologics platform. He has 20 years of experience in oncology research and drug development. He has advanced 6 immuno-oncology programs through IND-enabling studies and into the clinical trials in various leadership roles at Compass Therapeutics, Xilio Therapeutics, Takeda and Janux Therapeutics.
Seminars
Wednesday 9th September 2026
Tumor Selectivity Strategies Across Multispecifics, TCEs, & ADCs: What Have we Learnt so Far?
11:40 am
- Engineering conditional activation through masking and pre-dosing in TCEs and ADCs
- Discussing dual-target and multispecific approaches
- Applying induced proximity to ADC specificity to substantially change the behaviour of an ADC
